KR960701657A - 피부 상처 치료용 인자 XIII (Factor XIII for treatment of skin wounds) - Google Patents

피부 상처 치료용 인자 XIII (Factor XIII for treatment of skin wounds) Download PDF

Info

Publication number
KR960701657A
KR960701657A KR1019950704242A KR19950704242A KR960701657A KR 960701657 A KR960701657 A KR 960701657A KR 1019950704242 A KR1019950704242 A KR 1019950704242A KR 19950704242 A KR19950704242 A KR 19950704242A KR 960701657 A KR960701657 A KR 960701657A
Authority
KR
South Korea
Prior art keywords
factor xiii
treatment
use according
skin wounds
skin
Prior art date
Application number
KR1019950704242A
Other languages
English (en)
Other versions
KR100302935B1 (ko
Inventor
나오코 가토
다카시 오가와
슈지 곤도
Original Assignee
가토 에이치.
훽스트 제팬 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가토 에이치., 훽스트 제팬 리미티드 filed Critical 가토 에이치.
Publication of KR960701657A publication Critical patent/KR960701657A/ko
Application granted granted Critical
Publication of KR100302935B1 publication Critical patent/KR100302935B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C12N9/1044—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Materials Engineering (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

본 발명은 활성 성분으로서 사람 혈액 응고 인자 ⅩⅢ를 함유하는 피부 상처의 치료용 피부과 제제에 관한 것이다. 이 제제는 추가로 아프로티닌을 함유한다. 손상된 피부, 특히 화상 또는 화상을 입은 피부에 적용될 피부과용 제제는 정맥내 투여와 비교하여 활성 성분, 사람 혈액 응고 인자 ⅩⅢ를 우수하게 전달하고 의사의 도움없이 투여될 수 있다.

Description

피부 상처 치료용 인자 XⅢ(Factor XⅢ for treatment of skin wounds)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 피부 상처 국소 치료용 약제를 제조하기 위한 사람 혈액 응고 인자 ⅩⅢ의 용도.
  2. 제1항에 있어서, 추가로 아프로티닌를 사용하는 용도.
  3. 제1항 또는 제2항에 있어서, 피부 상처의 치료가 화상의 국소 치료인 용도.
  4. 제1항 또는 제2항에 있어서, 피부 상처의 치료가 용착의 국소 치료인 용도.
  5. 제1항에 있어서, 인자 ⅩⅢ가 사람 혈장으로부터 유래된 용도.
  6. 제1항에 있어서, 인자 ⅩⅢ가 사람 태반으로부티 유래된 용도.
  7. 제1항에 있어서, 인자 ⅩⅢ가 유전공학에 의해 생성되는 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950704242A 1993-03-30 1994-03-02 사람혈액응고인자xiii과아프로티닌을포함하는약제학적조성물 KR100302935B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP93-71395 1993-03-30
JP7139593 1993-03-30
PCT/IB1994/000040 WO1994022470A1 (en) 1993-03-30 1994-03-02 Factor xiii for treatment of skin wounds

Publications (2)

Publication Number Publication Date
KR960701657A true KR960701657A (ko) 1996-03-28
KR100302935B1 KR100302935B1 (ko) 2001-11-30

Family

ID=13459291

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950704242A KR100302935B1 (ko) 1993-03-30 1994-03-02 사람혈액응고인자xiii과아프로티닌을포함하는약제학적조성물

Country Status (7)

Country Link
EP (1) EP0691850B1 (ko)
KR (1) KR100302935B1 (ko)
AT (1) ATE224727T1 (ko)
AU (1) AU674061B2 (ko)
DE (1) DE69431430T2 (ko)
ES (1) ES2182840T3 (ko)
WO (1) WO1994022470A1 (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4784693A (en) 1992-07-24 1994-02-14 Oklahoma Medical Research Foundation Blockade of protein c activation reduces microvascular surgical blood loss
IL125983A0 (en) * 1998-08-30 1999-04-11 Yeda Res & Dev Pharmaceutical composition comprising factor xiiia
WO2003037249A2 (en) 2001-10-09 2003-05-08 Zymogenetics, Inc. Method for inhibiting the formation of seromas using factor xiii
AU2003230321B8 (en) 2002-05-09 2009-07-30 Medigenes A pharmaceutical composition for treatment of wounds containing blood plasma or serum
JP2004075661A (ja) * 2002-06-18 2004-03-11 Shiseido Co Ltd 表皮基底膜ケアを特徴とする皮膚外用剤、皮膚基底膜構造形成促進剤および人工皮膚の製造方法
EP1566183A1 (en) * 2004-02-20 2005-08-24 ZLB Behring GmbH Use of factor XIII for stimulating the perfusion of ischemic tissue
KR101897534B1 (ko) 2008-04-21 2018-09-12 노보 노르디스크 헬스 케어 악티엔게젤샤프트 건조한 트랜스글루타미나제 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265233A (en) * 1978-04-12 1981-05-05 Unitika Ltd. Material for wound healing
AT359653B (de) * 1979-02-15 1980-11-25 Immuno Ag Verfahren zur herstellung eines gewebekleb- stoffes
EP0268772B1 (en) * 1986-09-19 1995-04-26 ZymoGenetics, Inc. Expression of biologically active factor XIII
DE3808048A1 (de) * 1988-03-11 1989-09-21 Behringwerke Ag Verfahren zum affinitaetschromatografischen reinigen von faktor xiii
DE3829524A1 (de) * 1988-08-31 1990-03-01 Behringwerke Ag Verwendung von transglutaminasen als immunsuppressiva

Also Published As

Publication number Publication date
WO1994022470A1 (en) 1994-10-13
EP0691850B1 (en) 2002-09-25
DE69431430T2 (de) 2003-05-22
ES2182840T3 (es) 2003-03-16
EP0691850A1 (en) 1996-01-17
ATE224727T1 (de) 2002-10-15
KR100302935B1 (ko) 2001-11-30
AU674061B2 (en) 1996-12-05
DE69431430D1 (de) 2002-10-31
AU6155794A (en) 1994-10-24

Similar Documents

Publication Publication Date Title
US20040204391A1 (en) Method and composition for the treatment of scars
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
IL139231A0 (en) Preparations for the application of anti-inflammatory, especially antiseptic, agents and/or agents promoting the healing of wounds to the lower respiratory tract
DE69327432D1 (de) Heilmittel für wunden und hämorrhoiden
TR200200620T2 (tr) Levosimendan farmasötik solüsyonları
US5525335A (en) Wound healing agent
KR960701657A (ko) 피부 상처 치료용 인자 XIII (Factor XIII for treatment of skin wounds)
KR970032872A (ko) 아세틸살리실산을 함유하는 피부 손상 처치용 약물
KR890012659A (ko) 조산아의 뇌실내 출혈방지용 치료제
KR930019224A (ko) 유산 위험 치료제
Liebowitz et al. Anaphylactic reaction to chymotrypsin
KR890006665A (ko) 항-hiv 활성, 3'-아지도-2,6-디아미노푸린-2',3'-디데옥시리보사이드
Blandford Jr et al. Case report: successful homogenous skin graft in a severe burn using an identical twin as donor
KR950702433A (ko) Tcf-ii를 유효성분으로 하는 혈장 응고 정상화제
KR960700069A (ko) 상처 치료용 조성물(wound healing composition)
KR920703060A (ko) 제약학적 배합물
TWI263502B (en) Pharmaceutical preparation for treating ischemic disease of heart or limbs
CA2159609A1 (en) Factor xiii for treatment of skin wounds
KR910004186A (ko) 제약학적 배합물
KR910021244A (ko) 당뇨병성 괴저 치료제
SE8804214L (sv) Antiinflammatoriskt och antiinfektioest medikament
KR920005967A (ko) 순환계 질병치료와 미용약물 치료에 사용되는 성분물
NL7513892A (en) Ascorbic acid medicaments for external use - as nasal decongestants and to promote resistance to infection
RU2003344C1 (ru) Способ лечени ожоговой болезни
US20190209639A1 (en) Ointment for burn

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20100706

Year of fee payment: 10

LAPS Lapse due to unpaid annual fee